Sareum Holdings plc (LSE:SAR) has agreed a subscription for about £3.2 million at 14 pence a share, roughly 49% below its last closing price, with one warrant attached to each new share. Trading in its shares on AIM was restored on 26 October after a Capital Access Window, and a retail offer for up to £100,000 is open to existing shareholders.

What was announced

On Monday 26 October 2026, Sareum Holdings plc (LSE:SAR), a clinical-stage biotechnology company developing kinase inhibitors for autoimmune disease and cancer, issued three linked announcements. The first set out a subscription to raise approximately £3.2 million before expenses. The second gave the terms of a WRAP retail offer for up to £100,000. A third notice, timed at 7.30am, confirmed that the Capital Access Window had closed and trading had been restored.

Trading in the shares had been paused from 7.30am on 8 October 2026, when Sareum entered a Capital Access Window, a mechanism for a proposed share fundraise. With the fundraise completed subject only to admission of the new shares, the window closed.

The numbers

The subscription covers 22,807,143 new ordinary shares at 14 pence each, from new and existing investors. These include two new institutional investors introduced by Marex Financial. The price is a discount of approximately 49% to the closing mid-market price of 27.5 pence on 7 October 2026, the last business day before trading was paused. On the disclosed figures, the subscription shares will make up about 14% of the enlarged share capital of 162,533,325 shares, before any retail offer shares are issued.

Each subscription share carries one warrant, exercisable at 20 pence for three years from admission. The exercise price resets if the company later issues shares for cash at a lower price, and the warrants will not be admitted to trading. On the disclosed figures, full exercise of the warrants at 20 pence would bring in about £4.56 million, although there is no certainty any will be exercised.

The subscription is conditional only on admission, which is expected at 8.00am on or around 29 October 2026 and no later than 31 October.

The WRAP retail offer runs through the Winterflood Retail Access Platform, operated by Marex Financial. It offers up to 714,285 new shares at the same 14 pence price, with a minimum subscription of £100. It is open only to eligible UK retail investors who were shareholders before the announcement and who apply through a participating intermediary. Retail offer shares carry no warrants. The offer depends on the subscription completing, though the subscription does not depend on the offer. Commitments close at 4.30pm on 27 October, results are due on or around 28 October and admission is expected on 29 October.

Use of proceeds and pipeline

Sareum said the money will be used to take its lead programme, SDC-1801, to a Phase 2-ready position, to continue its neuroscience programme, and for general working capital alongside expected R&D tax credits. Details of the tax credits are due in its final results. No cash runway figure was given.

SDC-1801 is a selective oral TYK2/JAK1 inhibitor for autoimmune diseases. The company said Phase 1 results showed it was generally well tolerated, with a profile consistent with once-daily dosing. Its 16-week toxicology studies are concluding, and manufacturing and formulation work continues. The stated plan is to take the drug to Phase 2 and then out-license it. The announcement contains no executive quotes.

What to watch next

Directors could not join the subscription because they are in a closed period before audited results for the year to 30 June 2026. Those results are expected on or around 30 October. Some directors have indicated they may subscribe up to about £40,000 on the same terms after the results. The next milestones are the retail offer result, admission on 29 October, the final results and any director subscription.